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Abstract 
Error-free genome duplication and segregation are ensured through the timely activation of 
ubiquitylation enzymes. The anaphase-promoting complex/cyclosome (APC/C), a multi-
subunit E3 ubiquitin ligase, is regulated by phosphorylation. However the mechanism 
remains elusive. Using systematic reconstitution and analysis of vertebrate APC/Cs under 
physiological conditions, we show how cyclin-dependent kinase 1 (CDK1) activates the 
APC/C through coordinated phosphorylation between Apc3 and Apc1. Phosphorylation of 
the loop domains by p9/Cks2 (CDK regulatory subunit)-CDK1 controlled loading of co-
activator Cdc20 onto APC/C. A phosphomimetic mutation introduced into Apc1 allowed 
Cdc20 to increase APC/C activity in interphase. These results define a previously 
unrecognised subunit-subunit communication over a distance and the functional 
consequences of CDK phosphorylation. Cdc20 is a potential therapeutic target and our 
findings may facilitate the development of specific inhibitors. 
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One Sentence Summary: 
 
CDK1-dependent coordinated phosphorylation operating between Apc3 and Apc1 leads to 
activation of the APC/C ubiquitin ligase and trigger anaphase.  
 
Main Text:  
 
Many biological processes are regulated by post-translational modifications such as 
phosphorylation and ubiquitylation. The anaphase-promoting complex or cyclosome (APC/C) 
(1-3) is an unusually large multi-subunit (>13) enzyme and key component of the cellular 
machinery that regulates cell cycle progression and genome stability by catalysing ubiquitylation 
of regulatory proteins such as securin and cyclin B leading to their proteolysis (4-6). The activity 
of the APC/C controls mitotic exit. Anti-microtubule agents that disrupt spindle function are 
effective in the clinic because they cause mitotic delay, which triggers apoptosis of cancer cells. 
However, microtubules have key roles in neuronal functions, so the development of agents that 
block cells in mitosis without altering microtubules is important. One way to do this would be to 
target the APC/C (7-11). Mitotic kinases, including cyclin-dependent kinase 1 (CDK1), 
phosphorylate vertebrate APC/C at more than 50 sites during mitosis (12, 13) and the co-
activator subunit Cdc20 preferentially binds to and activates phosphorylated APC/C (14-16). 
However, all the evidence in vertebrates that CDK1 activates the APC/C comes from in vitro 
phosphorylation/ubiquitylation studies, and no mutagenesis of these sites has been done. To 
elucidate how CDK phosphorylates and activates the APC/C, we reconstituted recombinant 
Xenopus APC/C by simultaneous co-expression of all the subunits using an advanced 
baculovirus/insect cell expression system (17, 18) (fig. S1, A and B). The activities of purified 
APC/C were assessed under physiological conditions in a cyclin B destruction assay 
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reconstituted in Xenopus egg extracts. Incubation of reconstituted recombinant APC/C in extract 
from which endogenous APC/C was depleted (∆APC/C+APC/C) revealed that the reconstituted 
APC/C was active and degraded a substrate, cyclin B (fig. S1, C and D). The purified APC/C 
also ubiquitylated and degraded substrates in a Cdh1-dependent manner (fig. S1, E and F). Cdh1, 
an alternative co-activator of the APC/C in G1, activates the APC/C independently of subunit 
phosphorylation. These results indicated that our reconstituted Xenopus APC/C was functional. 
We mutated all conserved (between Xenopus and humans) CDK consensus phosphorylation sites 
of each individual subunit to alanine (A) and made mutant APC/Cs, one subunit at a time (table 
S1). The cyclin destruction assay in anaphase revealed that only APC/CApc1-15A (the reconstituted 
APC/C containing mutated 15 CDK sites on Apc1) and APC/CApc3-12A mutants showed 
decreased activity (Fig. 1A and fig. S2A). The integrity of the APC/C was confirmed in a Cdh1-
dependent assay. The activities of APC/CApc3-12A and APC/CApc1-15A were similar to that of WT, 
albeit APC/CApc1-15A showed reduced activity (fig. S2, B and C). These results prompted us to 
further investigate Apc3 and Apc1.  
In the absence of a co-activator, the APC/C is always inactive. We examined the binding 
of Cdc20 to APC/CApc3-12A and APC/CApc1-15A. We confirmed that APC/CWT bound Cdc20 in a 
cell-cycle-dependent manner; binding was low in interphase and high in anaphase (Fig. 1B). 
Consistent with the destruction assay in anaphase, APC/CApc3-12A showed a lower affinity for 
Cdc20 than APC/CWT (Fig. 1B). Cdc20 also failed to bind APC/CApc1-15A in anaphase (Fig. 1C). 
No shift in the electrophoretic band containing Apc3 or Apc1 was detected in anaphase extract 
for APC/CApc3-12A or APC/CApc1-15A respectively (Fig. 1, B and C), consistent with the mutated 
CDK sites no longer being phosphorylated. This was confirmed by in vitro phosphorylation 
using purified CDK1-cyclin B (Fig. 1D).  
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Why is the phosphorylation of two subunits, Apc3 and Apc1, of particular importance? 
Cdc20 directly binds the Apc3 subunit through the C-terminal IR (Ile-Arg) motif of Cdc20 (19). 
However, because the sites phosphorylated by CDK (except S567) are distant from 
tetratricopeptide repeat (TPR) motifs implicated in engaging co-activator IR motifs, the role of 
CDK might not be simply to increase the affinity of Apc3 to Cdc20 by phosphorylation. The 
twelve CDK sites on Apc3 are widely spread throughout the protein (Fig. 2A). To understand the 
CDK-driven APC/C activation mechanism, we constructed several mutant APC/Cs carrying 
CDK mutations in Apc3 and tested the activities (fig. S3). Mutations within the dimerization 
domain (T68A/S150A) or adjacent to the IR-binding domain (S567A) had no impact on APC/C 
activity. In contrast, CDK mutations in the predicted loop domain (Apc3-7A, -8A and -9A) 
reduced APC/C activity in anaphase as seen with Apc3-12A, highlighting the importance of loop 
domain phosphorylation (fig. S3, A to C). APC/CApc3-7A, APC/CApc3-8A and APC/CApc3-9A mutants 
also showed reduced Cdc20 binding in anaphase extract (Fig. 2B, lanes 16-20). Although the 
predicted loop domain comprises approximately 280-residue-sequences conserved among 
vertebrates (fig. S4), the function remains uncharacterised. Complexes of the Xenopus p9 protein 
(Suc1 or Cks1/2 in other organisms) (20) with CDK1 only bound to WT APC/C when 
phosphorylated in anaphase, but not interphase (Fig. 2B and fig. S5A). The Apc3 loop mutants 
failed to bind p9-CDK1 (Fig. 2B, lanes 17-19), consistent with findings that p9 is required for 
phosphorylation of Apc3 in anaphase (15, 21, 22). The Suc1/Cks family of proteins may 
recognise CDK sites and stimulate phosphorylation-dependent CDK signalling (23, 24). Thus, 
CDK phosphorylation of the loop domain in Apc3 might recruit p9-CDK1 and lead to 
phosphorylation of Apc1, another key CDK target in the APC/C. Furthermore, we examined the 
physical interaction between Apc3 fragments and p9. A bacterially purified fragment from the 
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loop domain (residues 202-342) bound to p9 in mitotic egg extracts, whereas the same fragment 
with CDK site mutations did not bind p9 (fig. S5B). These results indicate that Apc3 functions as 
a scaffold for p9-CDK1 through the loop domain. 
To investigate the mechanism of Apc1 phosphorylation-dependent APC/C activation, we 
sought to identify key phosphorylation sites on Apc1 (Fig. 2C). We made a series of mutant 
Apc1-APC/Cs (fig. S6A). The construct with CDK mutations in a predicted flexible loop domain 
(Apc1-7A) reduced cyclin destruction in anaphase whereas all the others showed similar more 
rapid cyclin B destruction kinetics (fig. S6, B and C and fig. S7). In a Cdh1-supplemented 
destruction assay, all the constructs showed similar activity to APC/CWT (fig. S6, D and E). 
Cdc20 loading was also assessed. Cdc20 loading to the APC/C in anaphase was abolished by the 
7A mutation (Fig. 2D, lane 25) whereas in interphase extract APC/CApc1-7A retained basal Cdc20-
binding as seen with APC/CWT (Fig. 2D, lanes 15 and 18). These results indicate that 
phosphorylation of the loop domain mutated in APC/CApc1-7A is necessary for Cdc20-binding and 
subsequent APC/C activation. To verify the relationship between Apc1 and Apc3 
phosphorylation, we raised a phospho-specific antibody that bound to the Apc1 loop domain 
only when S314 and S318 were phosphorylated (fig. S8). The specificity of this antibody was 
verified with bacterially produced peptide containing Apc1 residues 294-399 (hereafter Apc1loop) 
incubated either in anaphase or interphase extract (fig. S8, A and C). The CDK sites on Apc1loop 
were barely phosphorylated in Apc3 CDK site mutant APC/Cs whereas they were highly 
phosphorylated in APC/CWT in anaphase (Fig. 2E). Thus CDK phosphorylation in Apc1loop 
appears to depend upon Apc3 phosphorylation, highlighting that Apc3 influences Apc1 by 
recruitment of p9-CDK1.  
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Because both APC/CApc1-7A and APC/CApc3-9A retain some APC/C-dependent cyclin 
destruction activity, we tested the phenotype of the double mutant. APC/CApc3-9A/Apc1-7A appeared 
more deficient in cyclin destruction than APC/CApc1-7A or APC/CApc3-9A alone (Fig. 3A and fig. 
S9). APC/CApc3-9A/Apc1-7A failed to destroy cyclin A and securin as well (Fig. 3B). We also 
investigated the activity of APC/CApc3-9A/Apc1-7A using a “cycling” frog egg extract where the 
endogenous APC/C is replaced by APC/CApc3-9A/Apc1-7A (fig. S10). Unlike WT, APC/CApc3-9A/Apc1-
7A could not support cyclin or securin destruction. Consistently, an in vitro phosphorylated 
APC/CApc3-9A/Apc1-7A showed less activity than APC/CWT in an in vitro ubiquitylation assay (Fig. 
3C and fig. S11). Thus, phosphorylation of Apc1 and Apc3 subunits is crucial for APC/C 
activation. However, it is conceivable that phosphorylation of other subunits or an alternative 
pathway (e.g. phosphatases) might be involved to some extent in vivo (Fig. 3A and fig. S12). 
Nevertheless, if phosphorylation of Apc3 and Apc1 is important, an Apc1 phosphomimetic 
mutation (Asp: D) might bypass both Apc3 and Apc1 phosphorylation making CDK 
phosphorylation dispensable. We tested this in interphase extracts, in which neither CDK nor 
APC/C-Cdc20 is active. If Apc1 had the phosphomimetic mutation (7D), the APC/C was 
activated by Cdc20 even in interphase, triggering cyclin B destruction, albeit with slower 
kinetics than those observed with APC/C in anaphase (Fig. 3D and fig. S13A). The Apc1-7D 
gain-of-function phenotype was further confirmed by a “cycling” extract and an in vitro 
ubiquitylation assay (fig. S13, B and C). These results indicate that the phosphorylation status of 
the Apc1loop is a crucial determinant of Cdc20 loading and activation of the APC/C.  
We found that in co-immunoprecipitation assays, Apc1loop-7A (Apc1loop carrying 7A 
mutation) bound to the APC/C in anaphase extract whereas WT Apc1loop fragment did not (Fig. 
3E). Conversely, these phosphomimetic mutations abolished the interaction with the APC/C (fig. 
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S14), highlighting that interaction of the Apc1loop with the APC/C depends on its 
phosphorylation status. In the atomic structure of human APC/CCdh1.Emi1 determined using cryo-
EM (25), residues corresponding to the Apc1loop are disordered and not observed in the EM 
density map. However given the putative location of Apc1loop proximal to Cdh1NTD (25) (fig. 
S15), phosphorylation-dependent structural changes of Apc1loop could influence the APC/C 
binding sites for the NTD of co-activator located on Apc8 (25, 26), the PC domain of Apc1 (25), 
and Apc6 (26). Consistent with this idea, Cdc20-NTD binding was reduced in APC/CApc1-7A, 
compared with APC/CWT (Fig. 3F).  
 Our results reveal the presence and importance of the coordinated phosphorylation of 
Apc3 and Apc1 within the APC/C complex for the control of the APC/C in mitosis (Fig. 4). 
Extended flexible loops in both subunits have a key role; one acts as a scaffold of p9-CDK1 and 
the other for phosphorylation-dependent interaction with Cdc20-NTD. Previous studies in yeast 
and Drosophila provide in vivo evidence that CDK1 phosphorylation of the APC/C is required 
for its mitotic activity (22, 27, 28). Our present study extends past findings (13-16, 22) and 
uncovers the mechanistic insight and the functional consequences of APC/C phosphorylation in 
vertebrates. Cdc20 (not Cdh1, which is a tumour suppressor (29)) is a promising anti-cancer 
therapeutic target (7, 8, 10, 30). The Apc1loop may provide a target for strategies to specifically 
inhibit APC/C-Cdc20. 
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Figure legends 
 
Figure 1. Effect of phosphorylation of Apc3 and Apc1 on APC/C-Cdc20 activation.  
(A) Cyclin destruction assay in Xenopus egg extracts. APC/C-depleted extracts (∆APC/C) were 
supplemented with a range of reconstituted APC/Cs with CDK site mutations. Samples taken at 
indicated time points after addition of cyclin were analysed by SDS-PAGE and autoradiography. 
Quantification of fig. S2A. The relative cyclin levels are shown, normalized with reference to the 
intensities found at time 0 for each time point. (B) WT APC/C or APC/CApc3-12A was incubated 
with ∆APC/C interphase or anaphase extract. The APC/C was recovered with anti-Apc3 beads 
and bound Cdc20 was analysed by SDS–PAGE and immunoblotting. (C) Same as (B), but 
APC/CApc1-15A was used. (D) Phosphorylation of APC/CApc3-12A and APC/CApc1-15A by CDK1-
cyclin B. Left: WT APC/C or APC/CApc3-12A was incubated with CDK1-cyclin B and p9 in the 
presence of [γ-32P] ATP at 23˚C for indicated minutes. The APC/C was recovered using anti-
Apc3 affinity beads, and analysed by SDS-PAGE and autoradiography. Right: Same as left panel 
but APC/CApc1-15A was used.  
 
Figure 2. Interaction of phosphorylation on Apc3 and Apc1 subunits. 
 10 
(A) Schematic diagram of Apc3. CDK sites shared between Xenopus and Human Apc3 are 
shown in black. (B) WT APC/C or Apc3 mutant APC/Cs were incubated with ∆APC/C 
interphase or anaphase extracts. The APC/C was recovered with anti-Apc3 beads and bound 
proteins were analysed by immunoblotting. LC; IgG light chain. (C) Schematic diagram of 
Apc1. CDK sites shared between Xenopus and Human Apc1 are shown in black. (D) Binding of 
Cdc20 to APC/C in anaphase. WT APC/C or Apc1 mutant APC/Cs were incubated with 
∆APC/C interphase or anaphase extracts. APC/C was recovered with anti-Apc3 beads and bound 
proteins were analysed by immunoblotting. (E) Phosphorylation of WT or Apc3 mutant APC/Cs 
incubated in ∆APC/C extracts and then recovered with anti-Apc3 beads as detected by 
immunoblotting with pS314pS318 antibody and indicated APC/C antibodies.   
 
Figure 3. Role of CDK phosphorylation in the activation of the APC/C ubiquitin ligase. (A) 
Cyclin destruction assay in mock or ∆APC/C anaphase extracts supplemented with APC/CWT, 
APC/CApc1-7A, APC/CApc3-9A or APC/CApc3-9A/Apc1-7A (fig. S9). Same as Fig. 1A, relative cyclin 
levels are shown. (B) Same as (A), but human cyclin A2 or Xenopus securin destruction was 
examined in ∆APC/C anaphase extract supplemented with WT or Apc3-9A/Apc1-7A double 
mutant APC/C. (C) WT APC/C or APC/CApc3-9A/Apc1-7A was phosphorylated by p9-CDK1-cyclin 
B. APC/Cs recovered using anti-Apc3 affinity beads were subjected to cyclin B ubiquitylation 
assay in the presence/absence of Cdc20. 35S-labelled cyclin B was used as substrate. Samples 
taken at indicated time points were analysed by SDS–PAGE and autoradiography. The APC/Cs 
used were monitored by anti-Apc3 and anti-Apc5 immunoblotting. (D) Cyclin destruction assay 
in interphase extracts supplemented with APC/CWT, APC/CApc3-9A or APC/CApc3-9A/Apc1-7D (fig. 
S13A). Error bars, s.e.m. from three independent experiments. (E) Bacterially purified Flag-
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tagged Apc1 fragment (294-399 WT) or its 7A mutant was incubated with interphase or 
anaphase extract, immunopurified by anti-Flag beads and bound proteins analysed by 
immunoblotting. (F) Interaction of Cdc20 NTD with APC/CWT or APC/CApc1-7A. APC/C 
complexes were incubated with Cdc20 NTD (N159-5A) in interphase or anaphase extract 
depleted of endogenous APC/C and Cdc20 (∆APC/C ∆Cdc20). APC/C was recovered with anti-
Apc3 beads and bound proteins were analysed by immunoblotting.  
 
Figure 4. Proposed model for CDK1 activation of the APC/C. Top: CDK1 phosphorylates the 
APC/C and stimulates Cdc20 loading and subsequent ubiquitylation catalysis (‘active’). 
Conversely, at the end of mitosis, the APC/C is dephosphorylated by an as-yet-unidentified 
phosphatase(s), contributing to the inactivation of APC/C-Cdc20. Bottom: CDK1-dependent 
phosphorylation-relay for activation of the APC/C. p9-CDK1-cyclinB initially phosphorylates 
the internal loop domain of Apc3, which allows p9 (Cks2) bound CDK1-cyclin B loading to 
Apc3. p9-CDK1-cyclin B then stimulates phosphorylation of the internal loop domain of Apc1. 
The loop domain seems to block Cdc20-NTD access to the APC/C (e.g. Apc8) when it is not 
phosphorylated, but upon phosphorylation, the loop looses its inhibitory function, allowing 
Cdc20 NTD loading and subsequent ubiquitylation catalysis. 
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Supplementary Materials:  
Materials and Methods 
Cloning and expression of recombinant Xenopus APC/C (APC/C)  
The approach used in this study is based on the modified MultiBac pFBDM and pUCDM 
system allowing USER ligation-independent cloning (17, 18). Xenopus APC/C genes, 
apart from Apc1, were amplified by PCR using Xenopus laevis cDNA library. For Apc1, 
Xenopus tropicalis Apc1 was amplified from the IMAGE clone of Xenopus tropicalis 
Apc1 (Source BioScience). All APC/C genes amplified were cloned into pOENmyc 
vector with polH promoter and SV40 terminator for Apc2, Apc3, Apc7, Apc8, Apc11 
and Apc13 or p10 promoter and HSVtk terminator for Apc1, Apc4, Apc5, Apc6, Apc10, 
Apc12 and Apc16. TEV cleavable tandem Strep II-tag was fused to Apc6 at C-terminus 
(Apc6-strep) for affinity purification. Mutant APC/Cs were generated by PCR-based 
mutagenesis at this step and then all APC/C genes were further cloned into MultiBac 
vectors creating one pF1 vector-derivative pFUBB carrying Apc3, Apc8 and Apc7 at 
MUM1 site and Apc5, Apc4 and Apc6-strep at MUM2 site and a second pF1 vector-
derivative pFUBB carrying Apc2 and Apc11 at MUM1 site and Apc1 and Apc10 at 
MUM2 site. A pU1 vector-derivative pUUBB carrying Apc13 at MUM1 site, and Apc12 
and Apc16 at MUM2 site was also created. The resultant recombinant transfer vectors 
were transformed into MultiBacDH10cre cells to generate bacmids by in vivo 
recombination using the Tn7 sites of the pFUBB vector and the Cre-Lox site of the 
pUUBB vector. Bacmid 1 incorporated Apc3, Apc8, Apc7, Apc5, Apc4, Apc6-strep, 
Apc13, Apc12 and Apc16 and Bacmid 2 incorporated Apc2, Apc11, Apc1 and Apc10. 
Sf9 insect cells were transfected with bacmids 1 and 2 to generate recombinant 
baculoviruses. To express APC/C complex, High Five insect cells (Invitrogen) at a cell 
density 1.5 x 106 were co-infected with the two recombinant baculoviruses at an MOI 
(multiplicity of infection) of 1 for each virus and incubated at 27 °C for 48h with shaking 
(150 rev/min). The cells were harvested, frozen in liquid nitrogen and stored at -80 °C. 
 
Purification of APC/C 
All purification steps were performed at 4 °C. Cell pellets were thawed on ice and 
resuspended in APC/C lysis buffer [50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5% 
glycerol, 2 mM DTT, 0.5 mM EDTA, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 10 
µg/ml chymostatin, 30 units/ml benzonase (Novagen) ] and lysed by sonication. The 
lysate was centrifuged at 48,400 g for 60 min, the supernatant centrifuged again for 20 
min and the final soluble supernatant filtered through a 0.45 µm filter. This cleared lysate 
was loaded onto a 5 ml Strep-Tactin Superflow Cartridge (Qiagen) at a flow rate of 0.5 
ml/min. The column was washed with APC/C wash buffer [50 mM Tris-HCl pH 8.0, 250 
mM NaCl, 5% glycerol, 2 mM DTT] at a flow rate of 1.5 ml/min and recombinant 
APC/C was eluted with APC/C wash buffer containing 2.5 mM desthiobiotin (Sigma). 
Peak fractions were pooled and concentrated using Amicon Ultra (Millipore), and loaded 
onto Superose 6 HR 10/30 (GE Healthcare) equilibrated with APC/C SE-D buffer [20 
mM Hepes-NaOH pH 7.9, 500 mM NaCl, 2mM DTT, 0.01% n-Dodecyl b-D-maltoside, 
10 % glycerol].  
 Mutant APC/C activity was tested by incubating 1ml lysates with Strep-Tactin 
Superflow (Qiagen) beads (100 µl) at 4 °C for 1 h, washing with 3 x 1 ml of APC/C wash 
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buffer and elution with 2 x 300 µl of APC/C wash buffer containing 2.5 mM 
desthiobiotin. The eluted APC/C proteins were incubated with Dynabeads-Protein A 
conjugated to anti-Apc3 antibodies (AF3.1) and the bound-APC/C was washed with 
XBCSF buffer [10mM Hepes-KOH pH7.8, 50mM Sucrose, 100mM KCl, 2mM MgCl2, 
5mM EGTA] containing 0.01% NP-40, followed by XBCSF buffer alone. The APC/C 
bound beads were flash-frozen and stored at -80 °C. 
 
Preparation of Xenopus egg cell-free extracts 
Meiotic metaphase II-arrested (CSF) Xenopus laevis egg extracts were prepared as 
described (31). To prepare interphase extracts, CSF extracts were incubated at 23 °C for 
1.5 hr in the presence of 0.4 mM CaCl2 and 10 µg/ml cycloheximide, a protein synthesis 
inhibitor. Anaphase extracts were prepared by adding nondegradable GST-fused Xenopus 
cyclinB∆167 (a truncated cyclin B lacking the N-terminal 167 amino acids) to interphase 
extracts and incubating for 30 min at 23 °C. APC/C depleted (∆APC/C) or Cdc20 
depleted (∆Cdc20) extracts were prepared as reported previously (32, 33). Fresh cycling 
egg extracts were prepared as described (34).   
 
Cell-free destruction and ubiquitylation assays 
Destruction assays were performed essentially as described previously (33). Substrates 
were labelled with [35S]methionine (Hartmann Analytic, UK) in a coupled in vitro 
transcription-translation system (Promega, UK) and destruction assays were carried out 
using Xenopus egg cell-free extracts (anaphase or interphase extracts). The samples were 
taken at the indicated time points and analysed by SDS-PAGE and autoradiography. The 
images were analysed using Image J (NIH, USA) and the statistical analysis was 
performed using Prism GraphPad Software (CA, USA). Ubiquitylation assays were 
essentially performed as described (35). Reactions were carried out at 23 °C in 10 µl of 
buffer (20 mM Tris-HCl pH 7.5, 100 mM KCl, 2.5 mM MgCl2 , 2 mM  ATP, 0.3 mM  
DTT) containing 10 ng/µl APC/C, 0.05 mg/ml E1, 0.025 mg/ml UbcX, 0.75 mg/ml 
ubiquitin, 1 µM  ubiquitin-aldehyde, 150 µM  MG132, purified His-Cdh1 protein (or 
Strep-tag Cdc20), and 1 µl of 35S-labeled cyclin B (fission yeast Cdc13). The reactions 
were stopped at the indicated time points with SDS sample buffer and analysed by SDS-
PAGE and autoradiography. To prepare the APC/C phosphorylated by CDK1-cyclin 
B/p9, the APC/C was incubated in the XBCSF buffer containing 100 µM ATP in the 
presence of 10 ng/µl human CDK1-cyclin B (a kind gift of Dr. Endicott, Newcastle 
University, UK) (36) and 32 ng/µl Xenopus p9 (Cks2) at 23˚C for 40 min. The resultant 
APC/C was immunoprecipitated and washed by buffer (20 mM Tris-HCl pH7.5, 100 mM 
KCl, 2.5 mM MgCl2, 0.01% NP-40), and subjected to ubiquitylation. 
 
Phosphorylation assay 
For in vitro phosphorylation using purified p9-CDK1-cyclin B, WT or mutant 
recombinant APC/Cs bound to Dynabeads-Protein A conjugated to anti-Apc3 antibodies 
(AF3.1) were incubated in the XBCSF buffer containing 100 µM cold ATP and 1 
µCi/nmol of [γ-32P] ATP (Hartmann Analytic, UK) in the presence of 10 ng/µl human 
CDK1-cyclin B (36) and 32 ng/µl Xenopus p9 (Cks2) at 23˚C for 20 min or 40 min. For 
phosphorylation assay in Xenopus egg extracts, the APC/C was incubated with APC/C-
depleted egg extract in the presence of [γ-32P] ATP and cyclinB∆167 at 23˚C for 45 min. 
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The APC/C was immuno-precipitated and boiled in SDS sample buffer and analysed by 
SDS-PAGE and autoradiography.  
 
Immunoprecipitation of APC/C 
The APC/C was immunoprecipitated using Apc3 MAb (AF3.1) immobilized Dynabeads 
protein A. The bound proteins were washed twice with XBCSF_HS [XBCSF containing 500 
mM KCl and 0.01% NP-40], eluted with SDS sample buffer and analysed by SDS-PAGE 
and immunoblotting. 
 
Cloning and purification of Xenopus Apc1 fragments 
The fragment (294-399) of Xenopus tropicalis Apc1 was fused to 3xFlag tag at N-
terminus and 6xHis tag at C-terminus, and subcloned into pET vector. Mutants were 
generated by PCR-based mutagenesis. The resultant plasmids were introduced into 
BL21-CodonPlus (DE3) and the fusion proteins were expressed at 37 °C for 1hr in the 
presence of 1 mM IPTG. The cells were lysed by 0.3 mg/ml lysozyme, sonicated in lysis 
buffer [20 mM Hepes-NaOH pH 7.9, 500 mM NaCl, 5mM EGTA, 10 µg/ml leupeptin, 
10 µg/ml pepstatin A, 10 µg/ml chymostatin, 0.1 % Triton X-100, 10mM imidazole]. The 
proteins were purified from clarified lysate on Ni-NTA agarose beads (Qiagen). 
 
Binding assay using Xenopus Apc1 fragments 
Purified Apc1 fragments were incubated with Anti-Flag Affinity M2 beads (Sigma) at 4 
°C for 0.5-1h. Beads were washed with XBCSF buffer and incubated with interphase 
extract in the presence or absence of cyclin B∆167 at 23 °C for 45 min, separated from 
extract on Micro Bio-Spin columns (Bio-Rad), and washed twice with XBCSF buffer 
containing 0.1% NP-40. The bound proteins were eluted with SDS-sample buffer and 
analysed by SDS-PAGE and immunoblotting.   
 
Antibodies 
Antibodies used are as follows: anti-Apc1 (RbAb 4853, 1:100), Apc2 (RbAb 7577, 
1:500), Apc3/Cdc27 (1:200; BD Transduction Laboratories), Apc5 (RbAb 3445, 1:500), 
Apc6 (RbAb 3446, 1:500), Cdc20 (MAb BA8, 1:100), Xe-p9 (RbAb CE/R2, 1:50), 
phospho-Plx1 (MAb AZ44, 1:1000), Cdc2 (MAb A17, 1:3000). Apc1 phosphopeptide 
antibody (anti-pS314pS318, 1:1000) was raised in rabbits against LPH (the horseshoe 
crab Limulus polyphemus hemocyanin) conjugated phosphopeptide 
CVSKGEpSPTApSPFQN (BioGenes, Germany). Antibodies were affinity purified using 
a phosphopeptide column prepared with SulfoLink Kit (Pierce). After elution with 
ImmunoPure Gentle Ag/Ab Elution Buffer (Pierce), antibodies were dialysed against 
TBS and non-phosphospecific antibody was affinity depleted by passing through a 
column cross-linked with non-phosphopeptide CVSKGESPTASPFQN. The eluted 
phospho-specific antibodies were then enriched by dialysis against TBS containing 50% 
glycerol. 
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Fig.S1.  
Multi-subunit APC/C reconstitution and cell-free APC/C functional assays.  
(A) Schematic illustration of the expression of recombinant Xenopus apo-APC/C 
(APC/C). APC/C subunit genes were cloned into plasmid, and transferred into bacmid by 
recombination as shown. Red and blue circles are Tn7 transposition site and Cre-LoxP 
sites, respectively. The resultant two baculoviruses were used to co-infect High Five 
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insect cells and the APC/C was purified by affinity chromatography using Strept-Tactin 
resin. (B) Reconstituted WT APC/C was bound to a Strept-Tactin column, eluted by 
desthiobiotin, concentrated and applied to a Superose 6 column. The peak fraction was 
run on SDS-PAGE gradient gel, and stained with Coomassie Brilliant Blue (CBB). The 
CBB staining pattern confirms the high-purity and quality of expression of APC/C. (C) 
Xenopus egg cell-free extract based APC/C functional assay. APC/C substrates such as 
cyclin B can be degraded in Xenopus egg extract but if endogenous APC/C is depleted 
(∆APC/C), cyclin B becomes stable. Reconstituted APC/Cs that contain mutation(s) in 
any subunit(s) can be created and their activity tested in ∆APC/C extracts 
(∆APC/C+APC/C). (D) Reconstituted WT APC/C supports cyclin B destruction. Cdc20-
dependent cyclin destruction assay in Xenopus egg cell-free extracts. Mock or WT 
APC/C was incubated in ∆APC/C anaphase extract. 35S-labelled cyclin B and a version of 
cyclin B lacking the N-terminal 67 residues (∆67, stable control) were used as substrates. 
Samples taken at indicated time points after addition of substrates were analysed by 
SDS–PAGE and autoradiography. A lack of cyclin destruction in ∆APC/C anaphase 
extract was restored by adding back WT APC/C (lanes 15-21).  (E) Reconstituted WT 
APC/C is a functional ubiquitin ligase. WT APC/C (lanes 1-15) or none (lanes 16-30) 
was incubated with ubiquitylation factors (E1, E2, energy generating mix, ubiquitin) at 
23°C. 35S-labelled  cyclin B (fission yeast Cdc13) and purified Cdh1 were used as 
substrate and co-activator, respectively. Samples taken at indicated time points were 
analysed by SDS–PAGE and autoradiography. (F) Cdh1 can activate APC/C in 
interphase and trigger cyclin B destruction (lanes 1-6). Mock or WT APC/C was 
incubated in ∆APC/C interphase extract supplemented with Cdh1 (lanes 7-18). Please 
note that Xenopus eggs and early embryos lack Cdh1 until MBT (midblastula transition). 
35S-labelled cyclin B and a version of cyclin B lacking the N-terminal 67 residues (∆67, 
stable control) were used as substrates. A lack of cyclin destruction in ∆APC/C 
interphase extract was restored by adding back WT APC/C (lanes 13-18).   
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Fig. S2.  
A screening of APC/Cs harbouring CDK site mutations. (A) Cyclin destruction assay 
in Xenopus egg cell-free extracts. Mock or endogenous APC/C-depleted anaphase 
extracts (∆APC/C) were supplemented with a range of reconstituted APC/Cs (table S1). 
35S-labelled cyclin B and a version of cyclin B lacking the N-terminal 67 residues (∆67, 
stable control) were used as substrates. Samples taken at indicated time points after 
addition of substrates were analysed by SDS–PAGE and autoradiography. Quantification 
of the destruction assays is shown in Fig. 1A. (B) The activity of APC/C3-12A in 
interphase. Left panel: Mock, APC/CWT or APC/C3-12A mutant complex was incubated in 
APC/C-depleted (∆APC/C) interphase extract supplemented with Cdh1 and 35S-labelled 
APC/C substrates (cyclin B and ∆67). Samples taken at indicated time points after 
addition of substrates were analysed by SDS–PAGE and autoradiography. Right panel: 
Quantification of Left panel. Relative levels of cyclin B are shown. (C) The activity of 
APC/C1-15A in interphase. Same as (B), but APC/CWT or APC/C1-15A mutant complex was 
used. 
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Fig. S3  
The activities of a series of mutant APC/Cs carrying mutations in Apc3 in Xenopus 
egg anaphase extracts. (A) Schematic diagram of Apc3 and its phosphorylation site 
mutants. SP/TP sites shared between Xenopus and Human Apc3 are shown in black, 
mutated sites in red. (B) The activities of the indicated Apc3 mutant APC/Cs were 
assessed using cyclin destruction assay, like fig. S2A. (C) Quantification of the 
destruction assays (B). (D) The impact of S567 phosphorylation on APC activity was 
carefully investigated as S567 is located close to the IR-binding domain. WT or APC/Cs 
carrying S567 mutation (substitution to alanine, aspartic acid or glutamic acid) in the 
TPR domain (Apc3-S567A, Apc3-S567D, Apc3-S567E) were examined. The N576A 
mutant was used as a control because this residue is highly conserved among species and 
is known to be important for APC/C activity (19). (E) Quantification of the destruction 
assays (D).  
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Fig. S4.  
Alignment of predicted loop domains of vertebrate Apc3. Conserved CDK consensus 
phosphorylation sites (SP/TP) in a predicted Apc3 loop among vertebrates are 
highlighted in yellow (Hs; Homo sapiens human, Pt; Pan troglodytes chimpanzee, Mm; 
Mus musculus mouse, Gg; Gallus gallus chicken, Xl; Xenopus laevis frog, Xt; Xenopus 
tropicalis frog, Dr; Danio rerio zebrafish). 
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Fig. S5.  
The loop domain of Apc3 binds p9-CDK1 in a phosphorylation-dependent manner. 
(A) WT APC/C or APC/CApc3-12A was incubated with ∆APC/C interphase or anaphase 
extracts. The APC/C was recovered with anti-Apc3 beads and bound proteins were 
analysed by immunoblotting. Different volumes of APC/Cs were loaded to quantitatively 
examine levels of Cdk1 associated and Apc1 phosphorylation on APC/CApc3-12A, 
compared with WT APC/C. LC; IgG light chain. (B) Left panel: Schematic diagram of 
Apc3 fragments used. Right panel: Bacterially purified MBP-tagged Apc3 fragments 
were incubated with Xenopus egg CSF-arrested extracts for 20 min and Apc3 bound 
proteins were analysed by SDS–PAGE and immunoblotting. The loop domain fragment 
(residues 202-342) binds p9 in mitotic egg extracts, whereas the same fragment with 
CDK mutations (residues 202-342 6A) abolishes p9-binding activity. A similar length 
fragment from the N-terminal domain (residues 61-215) does not bind whereas a second 
fragment (residues 234-374) containing the loop domain is able to bind to p9 and CDK1, 
albeit with a weaker interaction than the loop domain fragment (residues 202-342).     
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Fig. S6.  
The activities of a series of mutant APC/Cs carrying mutations in Apc1 in Xenopus 
egg extracts. (A) Schematic diagram of Apc1 and its phosphorylation site mutants used. 
SP/TP sites shared between Xenopus and Human Apc1 are shown in black, mutated sites 
in red. (B) Cyclin destruction assay in anaphase extracts. The indicated mutant APC/C 
were incubated with ∆APC/C anaphase extracts and then substrates 35S-labelled cyclin B 
and ∆67 (as a stable control) were added. Samples taken at indicated time points after 
addition of substrates, were analysed by SDS–PAGE and autoradiography. (C) 
Quantification of the destruction assays (B). (D) Cyclin destruction assay in interphase 
extracts. Using the same APC/Cs as (B), the activities of indicated mutant APC/Cs were 
assessed by destruction assay in APC/C-depleted (∆APC/C) interphase extract 
supplemented with Cdh1 and 35S-labelled APC/C substrates (cyclin B and ∆67). Samples 
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taken at indicated time points after addition of substrates were analysed by SDS–PAGE 
and autoradiography. (E) Quantification of the destruction assays (D). 
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Fig. S7.  
Alignment of predicted loop domains of vertebrate Apc1. Conserved CDK consensus 
phosphorylation sites (SP/TP) in a predicted Apc1 loop among vertebrates are 
highlighted (Hs; Homo sapiens human, Pt; Pan troglodytes chimpanzee, Mm; Mus 
musculus mouse, Gg; Gallus gallus chicken, Xt; Xenopus tropicalis frog, Dr; Danio rerio 
zebrafish). Highly conserved (Yellow), Conserved apart from Mus musculus (Green), 
Conserved between Xenopus tropicalis and Danio rerio (Blue)  
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Fig. S8.  
The specificity of phospho-specific Apc1 antibody. (A) Schematic diagram of Apc1 
full length (FL) and its flexible loop domain fragments (residues 294-399): Apc1loop and 
Apc1loop-7A. The mutated CDK sites are in red. (B) Antibody binding to synthetic Apc1 
peptides with no phosphorylation (NP), phosphorylation at S314 and S318 (S314/S318-
Pho) or single site phosphorylation at S314 (S314-Pho). Peptides were spotted onto a 
nitrocellulose membrane and blotted with phospho-S314-S318 antibody (pS314pS318). 
(C) The pS314pS318 antibody specifically recognises Apc1 only when they are 
phosphorylated in anaphase. Bacterially purified Flag-tagged WT Apc1loop fragment was 
incubated in anaphase or interphase extracts for 45 min, purified using anti-FLAG 
affinity beads and analysed by immunoblotting with anti-Flag (Left: lanes 1-4) or anti-
pS314pS318 (Right: lanes 5-8) antibodies. An excess of the corresponding epitope 
phospho-peptide (lane 7) or the same non-phosphorylated peptide (lane 8: nonphospho-
peptide competitor) was incubated with the pS314pS318 antibody during 
immunoblotting. The pS314pS318 antibody recognises Apc1loop only when it is 
phosphorylated in anaphase (lanes 5 and 6) and the band disappears if the antibody is 
neutralized by the blocking peptide (lane 7).  
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Fig. S9.  
Phosphorylation of Apc1 and Apc3 subunits is crucial for APC/C activation.  
Upper panel: Cyclin destruction assay in mock or ∆APC/C anaphase extract or ∆APC/C 
anaphase extract supplemented with WT, Apc1-7A, Apc3-9A single or Apc3-9A/Apc1-
7A double mutant APC/Cs. 35S-labelled cyclin B and cyclin B lacking the N-terminal 67 
residues (∆67, stable control) were used as substrates. Samples taken at indicated time 
points after addition of substrates were analysed by SDS–PAGE and autoradiography. 
Quantification of the destruction assays is shown in Fig. 3A. Lower panel: 3D images of 
the APC/C showing WT Apc1 (cyan), Apc3 (green) and mutated subunits in red.  
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Fig. S10.  
The APC/CApc3-9A/Apc1-7A is inactive and unable to support cyclin B or securin 
proteolysis. Fresh “cycling” frog extracts and endogenous APC/C-depleted cycling 
extracts (∆APC) were prepared. WT or Apc3-9A/Apc1-7A double mutant APC/C (3-
9A/1-7A) was added back to ∆APC extracts. Egg extracts were incubated at 23˚C and 
samples were taken every 10 min for analysis. Apc3, cyclin B2, Cdk1 and securin were 
detected by immunoblotting. The control (mock) cycling extracts performed cycles of 
entry into and exit from mitosis, judging from band shifts of Apc3 and disappearance of 
cyclin B and securin whereas ∆APC never degraded cyclin B nor securin. WT APC/C, 
but not APC/CApc3-9A/Apc1-7A rescued ∆APC extracts, allowing cyclin B and securin 
destruction.  
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Fig. S11.  
In vitro phosphorylated APC/CApc3-9A/Apc1-7A is less active than APC/CWT in the 
presence of Cdc20.  Quantification of the ubiquitylation assays (Fig. 3C).   
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Fig. S12.  
Phosphorylation status of WT or CDK site mutant APC/Cs in anaphase egg extract 
and during in vitro phosphorylation by CDK-cyclin B. (A) WT APC/C, APC/CApc3-9A, 
APC/CApc1-7A or APC/CApc3-9A/Apc1-7A was incubated in ∆APC egg extract in the presence 
of [γ-32P] ATP and cyclinB∆167 at 23 ˚C for 45 min (‘anaphase’ extract). The APC/C 
was recovered using anti-Apc3 affinity beads as Fig. 1B and phosphorylation of APC/Cs 
was analysed by SDS-PAGE and autoradiography. The phosphorylation levels of Apc3-
9A and Apc1-7A mutant APC/Cs were decreased, compared with WT. Note that both 
Apc3-9A and Apc1-7A still contain CDK phosphorylation sites located in the non-loop 
domain and also under these conditions add-back APC/C can be phosphorylated by any 
mitotic kinases in Xenopus egg extracts. In anaphase extract, phosphorylation of Apc1 is 
reduced if phosphorylation of Apc3 is blocked (see also Fig. 2E). (B) WT APC/C, 
APC/CApc3-9A, APC/CApc1-7A or APC/CApc3-9A/Apc1-7A was incubated with CDK1-cyclin B 
and p9 in the presence of [γ-32P] ATP at 23˚C for 40 min. The APC/C was recovered 
using anti-Apc3 affinity beads, and analysed by SDS-PAGE and autoradiography. In 
purified p9-CDK1-cyclin B-dependent assay, phosphorylation of Apc1 is observed even 
if phosphorylation of Apc3 is blocked. The mechanism behind the difference between 
egg extracts and the purified CDK system remains unknown. 
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Fig. S13.  
The APC/CApc1-7D is more active than WT APC/C in interphase.  
(A) Cyclin destruction assay in interphase extracts. WT APC/C, APC/CApc3-9A or 
APC/CApc3-9A/Apc1-7D was incubated with ∆APC/C interphase extract and samples taken at 
indicated time points after addition of substrates were analysed by SDS–PAGE and 
autoradiography. Quantification of the destruction assays is shown in Fig. 3D. (B) 
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Endogenous APC/C was immunodepleted from fresh cycling extract (∆APC) and either 
WT or Apc1-7D mutant APC/C added back. Egg extracts were incubated at 23˚C and 
samples were taken every 10 min for analysis. Apc3, cyclin B2, phosphorylated Plx1 
(pPlx1:AZ44) and Cdk1 were detected by immunoblotting. As controls, mock and ∆APC 
extracts are shown. In the presence of APC/CApc1-7D, cyclin B does not sufficiently 
accumulate after the first mitotic exit (see between 60 min and 110 min) compared with 
WT APC add back and thus fails to enter the second mitosis which occurs at 120 min 
with WT APC/C. C) Unphosphorylated WT APC/C or APC/CApc1-7D was incubated with 
ubiquitylation factors (E1, E2, energy generating mix, ubiquitin) in the presence/absence 
of Cdc20 at 23°C. 35S-labelled cyclin B (fission yeast Cdc13) was used as substrate. 
Samples taken at indicated time points were analysed by SDS–PAGE and 
autoradiography. The amounts of APC/C used were monitored by anti-Apc3 
immunoblotting.  
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Fig. S14.  
Apc1loop binds to the APC/C depending on its phosphorylation status. Phospho-
mimetic mutation into Apc1loop abolishes the ability to interact with APC/C. Seven CDK 
sites in Flag-tagged Apc1 loop fragment were substituted to alanine, aspartic acid or 
glutamic acid with an additional mutation in 7D1E and 8E (T378E). Wild type Apc1 
fragment (WT) or its derivatives carrying mutations in CDK sites (7A, 7D, 7D1E or 8E) 
was incubated in anaphase extract and immunopurified with anti-FLAG affinity beads. 
Bound proteins were analysed by immunoblotting. M; molecular marker, staining pattern 
is a result of crossreaction with anti-Apc3 and anti-Apc6 antibodies. 
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Fig. S15.  
Location of Apc1, Apc3, Apc6, Apc8 and C box in human APC/C-Cdh1-Emi1 
complex. Top: The image was generated using the Protein Data Bank file (4UI9: 
APC/CCdh1.Emi1)(25) and PyMOL, highlighting Apc1 (cyan), Apc3A (green), Apc3B 
(light green), Apc6A (orange), Apc6B (light orange), Apc8A (blue), Apc8B (light blue) 
and the C box region (SKHGDRFIPSRAG, yellow). The PC domain of Apc1 (PC) and 
the N- and C- terminal residues of predicted loop domains of Apc1 and Apc3 are 
indicated. Note that each of Apc3, Apc6 and Apc8 forms symmetric V-shaped homo-
dimers through their N-terminal regions. Bottom: Closed view of the interaction interface 
of three subunits, Apc1, Apc8 and the C-box from Cdh1/Cdc20. The location of Apc1loop 
is not determined, but the assigned adjacent sites such as G290  (red) and P402 (orange) 
in Apc1 are very close to the interface between the C-box (yellow) and Apc8. 
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Table S1. CDK phosphorylation site mutant APC/C 
 
APC/C 
subunit 
No. of conserved  
CDK sites (SP/TP) 
APC/C 
mutant 
CDK mutation sites 
APC1 15 Apc1-15A S121A, T223A, T292A, S314A, S318A, S335A, S344A, S358A, 
S380A, S389A, T532A, T539A, S558A, S691A, S1352A 
APC2 2 Apc2-2A T303A, S648A 
APC3 12 Apc3-12A T68A, S150A, T206A, S242A, S277A, T280A, T290A, S292A, 
T343A, T360A, S365A, S567A 
APC4 3 Apc4-3A S22A, S481A, S503A 
APC5 2 Apc5-2A T31A, T235A 
APC6 1 Apc6-1A S558A 
APC7 4 Apc7-4A S38A, T92A, T134A, S523A 
APC8 4 Apc8-4A S544A, T565A, S571A, T579A 
APC10 4 Apc10-4A T3A, T7A, T90A, T160A 
APC11 0   
APC12 0   
APC13 0   
APC16 1   
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